This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Abraham TS, Rademaker A, West DP, Lacouture ME, Ortiz S.Economic impact in the management of dermatologic adverse drug reactions induced by the epidermal growth factor receptor inhibitor (EGFRI) erlotinib. 67th Annual Meeting of the American Academy of Dermatology: 55 abstr. P1163, 6 Mar 2009
Joshi S, West D, Witherspoon J, Lacouture M, Ortiz S.Quality of life in patients with epidermal growth factor receptor inhibitor-induced papulopustular rash compared to historically-reported QOL for common dermatologic disorders. 67th Annual Meeting of the American Academy of Dermatology: 46 abstr. P1129, 6 Mar 2009
Rights and permissions
About this article
Cite this article
Substantial economic and QOL impacts with DADRs to EGFRIs. Pharmacoecon. Outcomes News 575, 8 (2009). https://doi.org/10.2165/00151234-200905750-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905750-00014